Seeking men and women who have been diagnosed since January 1, 2020, with metastatic non-small cell lung cancer and have been or will be treated with immunotherapy, chemotherapy or a combination of the two for a study to develop a tool to help guide treatment decisions.
Seeking men and women with advanced relapsed, refractory, or resistant hematological (blood) cancer with an IDH mutation that has not responded or stopped responding to prior treatment for participation in a study of an investigational drug.
Seeking men and women whose non-small cell lung cancer (NSCLC) has spread outside the lungs, and has a change in the gene called EGFR (epidermal growth factor receptor) and has not yet been treated for a study of an investigational drug combination.
Seeking men and women with hormone receptor positive/ human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced inoperable or metastatic breast cancer for a study of an investigational drug combination.
Seeking men and women whose non-small cell lung cancer has spread or stopped responding to treatment and whose cancer has been tested and found to have a specific mutation in the KRAS gene known as KRAS (G12C) for a study of an investigational drug for targeted treatment against the KRAS (G12C) mutation.
Seeking men and women whose head and neck cancer has progressed following immune checkpoint inhibitor treatment for a study of an investigational drug combination.
Seeking men whose metastatic prostate cancer has responded exceptionally well to therapy that included a medication to decrease testosterone and a medication to prevent growth signals in the body from male hormones including testosterone for a study of interrupting hormone treatment to allow testosterone levels to recover.
Seeking men and women with urothelial (renal pelvis, ureter, bladder, or urethra) cancer that has spread to other places in the body (metastatic) for a study of an investigational drug combination.